1. Eldh M, Hammar U, Arnot D, Beck HP, Garcia A, Liljander A, Mercereau-Puijalon O, Migot-Nabias F, Mueller I, Ntoumi F, Ross A, Smith T, Sonden K, Vafa Homann M, Yman V, Felger I, Farnert A (2020) Multiplicity of asymptomatic Plasmodium falciparum infections and risk of clinical malaria: a systematic review and pooled analysis of individual participant data. J Infect Dis 221(5):775–785. https://doi.org/10.1093/infdis/jiz510
2. Farnert A, Arez AP, Babiker HA, Beck HP, Benito A, Bjorkman A, Bruce MC, Conway DJ, Day KP, Henning L, Mercereau-Puijalon O, Ranford-Cartwright LC, Rubio JM, Snounou G, Walliker D, Zwetyenga J, do Rosario VE (2001) Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg 95(2):225–232. https://doi.org/10.1016/s0035-9203(01)90175-0
3. Messerli C, Hofmann NE, Beck HP, Felger I (2017) Critical evaluation of molecular monitoring in malaria drug efficacy trials and pitfalls of length-polymorphic markers. Antimicrob Agents Chemother 61(1):e01500-16. https://doi.org/10.1128/AAC.01500-16
4. Snounou G, Beck HP (1998) The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 14(11):462–467. https://doi.org/10.1016/s0169-4758(98)01340-4
5. WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Report No. ISBN 978 92 4 159630 5. World Health Organisation. Geneva. 2008